Skip to main content
Prithviraj Bose, MD, Oncology, Houston, TX

PrithvirajBoseMD

Oncology Houston, TX

Hematologic Oncology

Assistant Professor, Internal Medicine, Virginia Commonwealth University School of Medicine

Dr. Bose is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Bose's full profile

Already have an account?

  • Office

    1515 Holcombe Blvd
    Houston, TX 77030
    Phone+1 713-792-6161
    Fax+1 713-794-4534

Education & Training

  • University of Oklahoma Health Sciences Center
    University of Oklahoma Health Sciences CenterFellowship, Hematology and Medical Oncology, 2007 - 2010
  • University of Oklahoma                                   Health Sciences Center
    University of Oklahoma Health Sciences Center2007 - 2010
  • Henry Ford Health/Henry Ford Hospital
    Henry Ford Health/Henry Ford HospitalResidency, Internal Medicine, 2005 - 2007
  • Spokane Teaching Health Center
    Spokane Teaching Health CenterInternship, Internal Medicine, 2004 - 2005
  • Medical College and Hospital Kolkata
    Medical College and Hospital KolkataClass of 2002

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2021 - Present
  • GA State Medical License
    GA State Medical License 2022 - 2026
  • TX State Medical License
    TX State Medical License 2015 - 2026
  • AL State Medical License
    AL State Medical License 2023 - 2025
  • AZ State Medical License
    AZ State Medical License 2022 - 2025
  • LA State Medical License
    LA State Medical License 2022 - 2025
  • MS State Medical License
    MS State Medical License 2022 - 2025
  • American Board of Internal Medicine Hematology
  • Join now to see all

Awards, Honors, & Recognition

  • Physician’s Recognition Award with Commendation American Medical Association, 2011
  • University Honors University of Calcutta, 1997
  • First Certificate of Honors in Biochemistry University of Calcutta, 1995
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Mutational Landscape of myelodysplastic/myeloproliferative Neoplasm – Unclassifiable (MDS/MPN-U)  
    Aziz Nazha, Rami S Komrokji, Andrew Sochacki, Mikkael A Sekeres, Prithviraj Bose, Courtney D DiNardo, Hagop M Kantarjian, Srdan Verstovsek, Sanam Loghavi, Jaroslaw P M..., Blood
  • Final Results of a Randomized Multicenter Phase II Study of Alvocidib, Cytarabine, and Mitoxantrone Versus Cytarabine and Daunorubicin (7+3) in Newly Diagnosed High-Ri...  
    Joshua F Zeidner, Mark R Litzow, Jeffrey E Lancet, Prithviraj Bose, Raoul Tibes, Ivana Gojo, Richard F Little, Judith E Karp, Leukemia Research
  • Cyclin dependent kinase inhibitor therapy for hematologic malignancies  
    Bose P, Simmons GL, Grant S, Expert Opin Investig Drugs, 5/6/2013
  • Join now to see all

Books/Book Chapters

Abstracts/Posters

  • Constitutively Activated STAT3 Induces the Production of PTX3 That Contributes to the Induction of Bone Marrow Reticulin Fibrosis in Patient with CLL
    Prithviraj Bose, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • A Phase II Trial of Azacitidine (AZA) in Combination with Ruxolitinib (RUX) in Myelodysplastic Syndrome/Myeloproliferative Neoplasms (MDS/MPNs)
    Prithviraj Bose, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Phase 2 Study of Ruxolitinib (RUX) in Combination with 5-Azacitidine (AZA) in Patients (pts) with Myelofibrosis
    Prithviraj Bose, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Join now to see all

Lectures

  • Present Strategies and Future Directions: Treating MDS and MPN 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Combined Ibrutinib and Venetoclax in Patients with Treatment-Naïve High-Risk Chronic Lymphocytic Leukemia (CLL) 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Novel BET Protein Degrader-Based Combinations Exert Lethality Against Human AML Resistant to BET Inhibitors Due to Increased Activity of β-Catenin-TCF7L2- MYC Axis 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Authored Content

  • Final Results of a Randomized Multicenter Phase II Study of Alvocidib, Cytarabine, and Mitoxantrone Versus Cytarabine and Daunorubicin (7+3) in Newly Diagnosed High-Risk Acute Myeloid Leukemia (AML)August 2018
  • Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA101) (iFCG) Treatment for First-Line Therapy of Patients with CLL with Mutated IGHV and Without Deletion 17pOctober 2017

Press Mentions

  • Asymptomatic or Minimally Symptomatic Myelofibrosis
    Asymptomatic or Minimally Symptomatic MyelofibrosisNovember 4th, 2024
  • Innovative Developments in Myelofibrosis Treatment Options
    Innovative Developments in Myelofibrosis Treatment OptionsAugust 16th, 2024
  • Momelotinib Maintains Superiority over Danazol for Myelofibrosis with Anemia
    Momelotinib Maintains Superiority over Danazol for Myelofibrosis with AnemiaDecember 14th, 2022
  • Join now to see all

Professional Memberships